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Abstract
The aim of this study was to assess whether lonid-
amine (LND) interferes with some steps in angio-
genesis progression. We report here, for the first time,
that LND inhibited angiogenic-related endothelial cell
functions in a dose-dependent manner (1–50 Mg/ml). In
particular, LND decreased proliferation, migration,
invasion, and morphogenesis on matrigel of different
endothelial cell lines. Zymographic and Western blot
analysis assays showed that LND treatment produced
a reduction in the secretion of matrix metalloprotei-
nase-2 and metalloproteinase-9 by endothelial cells.
Vessel formation in a matrigel plug was also reduced
by LND. The viability, migration, invasion, and matrix
metalloproteinase production of different tumor cell
lines were not affected by low doses of LND (1–10
Mg/ml), whereas 50 Mg/ml LND, which corresponds to
the dose used in clinical management of tumors,
triggered apoptosis both in endothelial and tumor
cells. Together, these data demonstrate that LND is a
compound that interferes with endothelial cell func-
tions, both at low and high doses. Thus, the effect of
LND on endothelial cell functions, previously unde-
scribed, may be a significant contributor to the
antitumor effect of LND observed for clinical manage-
ment of solid tumors.
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Introduction
Lonidamine (LND) is an antineoplastic drug that is effective
against a wide range of solid tumors [1–7]. It affects energy
metabolism [8], alters the plasma and mitochondrial mem-
branes [9,10], and interferes with DNA repair [11] and
cellular acidification [12]. Preclinical studies demonstrated
the ability of LND to increase the response of human tumor
cells to several antineoplastic drugs such as cisplatin [13],
etoposide [14] diazepam [15], adriamycin [16,17], and
paclitaxel [18]. We previously reported that LND triggers
apoptosis independently of the p53 gene [19] and that bcl-2
overexpression blocks LND-induced apoptosis [20]. LND
was also demonstrated to trigger apoptosis through a direct
bcl-2– inhibited effect on the mitochondrial permeability transi-
tion pore [9], and to favor mitochondrial membrane permeabi-
lization through a direct effect on adenine nucleotide
translocase [10]. Thus, unlike conventional antitumor drugs
that trigger proapoptotic signal transduction pathways up-
stream of mitochondria, LND acts directly on mitochondria to
induce apoptosis. Because mitochondria play a crucial role in
the induction and execution of apoptosis [21], recent sugges-
tions have been made to use agents that directly act on
mitochondria to trigger apoptosis so that drug-sensitive as well
as drug-resistant tumor cells can be eliminated.
Phase II and phase III trials demonstrated the efficacy of
LND on metastatic breast cancer [3], advanced ovarian cancer
[2,4], inoperable non small lung carcinoma [1,5], and glioblas-
toma multiforme [6].
The low toxicity observed after long-term exposure of neo-
plastic patients to LND [1,2,4,7] and the ability of LND to
potentiate drug efficacy led us to investigate the effect of
LND on angiogenesis. In recent years, the importance of
angiogenesis in tumor growth and the dissemination and use
of antiangiogenic agents have been widely discussed [22,23].
Most research works, to date, have concentrated on antiangio-
genic drugs that prevent the proliferation of vascular endothe-
lial cells, which are essential for the development of tumor
vasculature. The targeting of existing tumor vasculature repre-
sents a promising alternative approach [24–26]. Both depend
on targeting endothelial cells, rather than tumor cells, for drug
action, and destruction of the tumor cell is secondary.
We examined the effect of LND on in vitro endothelial
cell functions involved in angiogenesis, and show, for the first
time, that LND reduces in vitro endothelial cell proliferation,
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morphogenesis, migration, invasion, metalloproteinases se-
cretion, and vessel formation in a matrigel plug.
Materials and Methods
Endothelial and Tumor Cells
Human umbilical endothelial cells (HUVECs; PromoCell
GmbH, Heidelberg, Germany), were cultured in complete
EBM-2 medium (Clonetics Bio Whittaker, Walkersville, MD)
containing 2% fetal bovine serum. Human microvascular
endothelial cells (HMVECs) were kindly provided by
Dr. Gabriella Fibbi (Department of Pathology and Oncology,
University of Florence, Florence, Italy) and maintained in
MCDB-131 medium (Invitrogen, Milan, Italy) supplemented
with 0.3% fetal calf serum (FCS). Immortalized EA.hy926
cells [27] were maintained in Dulbecco’s modified Eagle’s
medium (DMEM; Invitrogen) with high glucose, supplement-
ed with 10% FCS, hypoxanthine aminopterin thymidine
medium, 2 mM L-glutamine, and antibiotics. Bovine aortic
endothelial cells (BAECs) were furnished by Dr. Carlo
Gaetano (Istituto Dermopatico dell’Immacolata, Rome, Italy)
and cultured in DMEM (1 g/l glucose) supplemented with
10% FCS and 1% glutamine and antibiotics. The experi-
ments were performed with early [5–10] cell passages. NIH
3T3 mouse embryo fibroblasts were cultured in DMEM
containing 10% FCS and 1% glutamine and antibiotics.
The JR8 melanoma, CG5 breast, ADFS glioblastoma, and
H460 lung human cell lines were cultured in RPMI 1640
medium (Invitrogen) supplemented with 10% FCS and
1% glutamine and antibiotics.
The conditioned media (CM) of endothelial, tumor, and
NIH 3T3 cells were prepared by incubating subconfluent
cells in serum-free medium (SFM) for 24 hours. The CM
were then collected under sterile conditions, centrifuged
sequentially at 1200 and 12,000 rpm for 10 minutes to
eliminate debris, and stored at 20jC.
LND Preparation
LND ([1-(2,4-dichlorobenzyl)-1H-indazole-3-carboxylic
acid] (Doridamine; Angelini Spa, Pomezia, Italy) was dis-
solved in dimethyl sulphoxide at a concentration of 10 mg/ml,
adjusted with isoton to 10 concentration, and brought to
the final concentration with completemedium. Control experi-
ments demonstrated that the doses of dimethyl sulphoxide
used through the study did not have any effect.
Cell Proliferation Assay
Exponentially growing endothelial cells, NIH 3T3 fibro-
blasts, JR8, CG5, ADFS, and H460 tumor cell lines were
seeded in 96-well plates (5  103 cells/well) and incubated
for 24 hours in complete medium. Then, the medium was
replaced with fresh complete medium and the cells were
incubated for 48 hours in the presence of increasing doses
of LND (ranging from 0.1 to 50 mg/ml). Cells exposed to
medium, with or without FCS, were used as positive and
negative control, respectively. Cell proliferation was evalu-
ated by a colorimetric assay at the end of treatment as
described previously [27]. Each dose of LND was tested in
sextuplicate. All the experiments were repeated at least
three times.
Analysis of Apoptosis
Approximately 5  105 endothelial and tumor cells were
plated in complete medium in 100-mm tissue culture Petri
dishes and incubated at 37jC. After 24 hours, cells were
exposed for 48 hours to LND at doses ranging from 1 to 50
mg/ml. Adherent cells recovered from the plates by phos-
phate-buffered saline (PBS)–EDTA 0.02% treatment were
washed, assayed for cell viability (trypan blue exclusion test),
and counted. The percentage of apoptotic cells was detected
by annexin V assay. Briefly, 1  106 cells were double-
stained with fluorescein isothiocyanate (FITC)–conjugated
annexin V and propidium iodide using the Vybrant Apoptosis
Kit according to the manufacturer’s instruction (Molecular
Probes, Eugene, OR) and were immediately analyzed by
cytofluorimetric analysis (FACScan; Becton Dickinson,
Milan, Italy) as previously reported [28]. The experiments
were repeated three times.
Morphogenesis Assay on Matrigel
Morphogenesis on matrigel of endothelial cell lines was
evaluated as reported previously [27]. Twenty-four–well
microtiter plates were coated with 300 ml/well unpolymerized
matrigel (10 mg/ml; Becton Dickinson) and allowed to poly-
merize for 1 hour at 37jC. Endothelial cells were plated
(2  105 cells/well) in 1 ml of SFM containing 50% NIH 3T3
CM (positive control), to which LND at different doses (1, 5,
and 7.5 mg/ml) was added. Cells plated in SFM served as the
negative control. After 8 and 24 hours of incubation in a 5%
CO2-humidified atmosphere at 37jC, cell growth was ob-
served through a reverted, phase-contrast photomicroscope
and photographed. Experiments were repeated at least three
times, and each dose was tested in triplicate.
Chemoinvasion and Chemotaxis Assays
These assays were performed in Boyden chambers as
previously described [29]. Briefly, endothelial (1.2  105
cells/800 ml) or tumor (2  105 cells/800 ml) cells were added
to the upper chamber in the absence or presence of increas-
ing concentrations of LND (from 1 to 50 mg/ml). The lower
compartment was filled with 200 ml of NIH 3T3 CM, or with
DMEM supplemented with 0.1% bovine serum albumin
(BSA) to evaluate random migration and invasion (negative
control). Vascular endothelial growth factor (VEGF; 30 ng/ml)
was also used as chemoattractant for the migration assay
on endothelial cells. The compartmentswere separated by an
8-mm pore size polycarbonate filter (Costar Corp., Cam-
bridge, MA), coated with matrigel (25 mg/filter) for chemo-
invasion, or gelatin (5 mg/ml; Sigma, Milan, Italy) for
chemotaxis. After incubation for 6 hours in a humidified 5%
CO2 atmosphere at 37jC, cells on the upper side of the filter
were removed mechanically and cells that had invaded or
migrated to the lower surface of the filter were fixed in ethanol
and stained with toluidine blue. Cells were counted in at least
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four high-power fields (HPFs;200). Each dosewas tested in
triplicate and experiments were repeated at least three times.
Zymography of Gelatinolytic Activity and Western Blot
Analysis
Subconfluent endothelial and tumor cells were incubated
for 48 hours in SFM in the absence or presence of increas-
ing doses of LND (1–50 mg/ml). CM of tumor cells were
concentrated with Centricon-30 concentrators (Amicon,
Danvers, MA). Then CM were analyzed by zymography
using gelatin-embedded sodium dodecyl sulphate polyacryl-
amide gel electrophoresis (SDS-PAGE) as previously de-
scribed [29].
The presence of matrix metalloproteinase-2 (MMP2) and
matrix metalloproteinase-9 (MMP9) proteins in CM was also
analyzed by Western blot analysis. Twenty microliters of
sample dilution buffer was boiled and electrophoresed under
reducing conditions on an 11% SDS-PAGE. Anti-MMP2
(NoeMarkers, Fremont, CA) and anti-MMP9 (Oncogene,
La Jolla, CA) antibodies were used at 1:1000 and 1:500
dilution, respectively. Red Ponceau staining (0.1% in acetic
acid; Sigma) of filter was used to check equal loading
of proteins.
The experiments were repeated two times.
In Vivo Matrigel Assay
To evaluate the ability of LND to modulate the neovascu-
larization within matrigel plugs, the method described previ-
ously was used [30]. Six hundred microliters of matrigel,
supplemented with VEGF (60 ng/mice; R&D Systems,
Minneapolis, MN), heparin (19.2 U; Schwarz Pharma SpA,
Milan, Italy), and 60 ml of LND at two different doses (1 and
5 mg/ml), was injected subcutaneously into the flank of
8-week-old C57BL/6 mice (furnished by the Animal Care Unit
of Regina Elena Cancer Institute, Rome, Italy). The negative
and positive controls contained heparin alone or heparin plus
VEGF, respectively. After 5 days, the angiogenic response
was evaluated by macroscopic analysis at autopsy, and by
measurement of the hemoglobin (Hb) content into the pellet
of matrigel as previously reported [30]. Histologic analysis of
matrigel plugs was also performed using Masson Trichrome
stain.
The values were expressed as optical density (OD)/100
mg of matrigel. Each group consisted of eight animals. The
experiments were repeated four times.
Statistical Analysis
Student’s t test analysis was used to compare untreated
and LND-treated samples.
Figure 1. Low doses of LND inhibit endothelial cell proliferation while not inducing apoptosis. (A) HUVEC proliferation was evaluated after exposure for 48 hours to
doses of LND ranging from 0.1 to 50 g/ml (black column). (B) Cell proliferation of HMVEC (dark grey column), EA.hy926 (pale grey column), and BAEC (white
column) was evaluated after exposure for 48 hours to 10 g/ml LND. Cells exposed to medium with or without 10% FCS were used as positive (+) and negative ()
control, respectively. (C) Flow cytometric analysis of annexin V was performed by exposing HUVEC and EA.hy926 endothelial lines to doses of LND ranging from 1
to 50 g/ml for 48 hours. The percentage of annexin V–positive cells is reported. Each value is the mean of sextuplicate ±SD, and the data are representative of at
least three separate experiments (A and B). A representative experiment out of three is reported (C). Statistical differences between LND-treated versus untreated
groups: *P < .05; **P < .01.
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Results
LND Inhibits Endothelial Cell Proliferation
We previously demonstrated that LND induces apoptosis
in breast cancer and glioblastoma lines at the dose of 50
mg/ml [19,20], whereas other authors evidenced the ability
of LND to trigger the apoptotic program in leukemic cells at
the dose of 65 mg/ml [14]. Therefore, with the aim of evalu-
ating the potential antiangiogenic activity of LND, several
endothelial cell lines with different origins were exposed to
LND doses ranging from 0.1 to 50 mg/ml and cell proliferation
was evaluated 48 hours after LND treatment. Cells exposed
to medium with or without FCS were used as positive and
negative control, respectively. As reported in Figure 1A, LND
inhibited the proliferation of HUVEC in a dose-dependent
manner. A significant (P < .01) decrease in cell proliferation
was observed after exposure of endothelial cells to LND
doses ranging from 1 to 50 mg/ml, whereas no effect on
proliferation was observed after 0.1 mg/ml LND treatment.
The ability of LND to reduce proliferation of other endothelial
cells was also evaluated. As reported in Figure 1B, 10 mg/ml
LND significantly (P < .01) inhibited the growth of HMVEC,
EA.hy926, and BAEC lines by approximately 50%, 30%,
and 25%, respectively.
To check whether LND exhibits its antiproliferative activity
through the induction of apoptosis, HUVEC and EA.hy926
endothelial lines were analyzed for the presence of early
apoptotic events on annexin V staining. As reported in Figure
1C, a very low percentage of annexin V–positive cells (less
than 8%) was observed after treatment of cells with LND
at doses ranging from 1 to 10 mg/ml for 48 hours. On the
contrary, 50 mg/ml LND induced apoptosis in the two endo-
thelial cell lines even though a different degree of apoptosis
was observed. In particular, about 30% and 20% of HUVECs
and EA.hy926 endothelial cells, respectively, were annexin
V–positive after LND treatment.
LND Inhibits Endothelial Cell Migration and Invasion
Angiogenesis is highly dependent on endothelial cell
motility and invasion. We therefore tested the effect of LND
on these two endothelial cell functions. As shown in Figure 2,
LND significantly inhibited HUVEC and HMVEC migration
(Figure 2A) and invasion (Figure 2B) in a dose-dependent
manner. Cells strongly migrated and invaded in response to
NIH 3T3 CM (positive control), whereas migration and inva-
sion in the absence of a chemoattractant (negative control)
were limited. The presence of 1 mg/ml LND during the
migration assay was able to significantly (P < .05) inhibit
Figure 2. LND inhibits HUVEC (black column) and HMVEC (white column) migration (A and C) and invasion (B). Cultured cells were dissociated into a single cell
suspension, suspended in DMEM supplemented with 0.1% BSA, and incubated for 6 hours on top of gelatin-coated filters (A and C), or on filters coated with
matrigel (B) in the absence (positive and negative control) or presence of LND (1, 5, and 50 g/ml). The migration was evaluated by filling the lower compartment
with NIH 3T3 CM (A) or VEGF (C). The invasion was evaluated in response to NIH 3T3 CM (B). DMEM supplemented with 0.1% BSA was used as negative control
to evaluate random migration and invasion. The migrated or invaded cells were counted in at least four HPFs (200). Each value is the mean of triplicates ±SD,
and the data are representative of at least three separate experiments. Statistical differences between LND-treated versus untreated groups (positive control):
*P < .05; **P < .01.
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the migration of the two endothelial lines by about 30% and
this inhibition was progressively enhanced with increasing
doses (about 50% and 80% inhibition at doses of 5 and 50
mg/ml, respectively; P < .01). Similar results were obtained
when VEGF was used as chemoattractant for the migration
assay. Inhibition of about 35%, 55%, and 75% at the doses
1, 5, and 50 mg/ml, respectively (P < .01), were observed
(Figure 2C). When all the endothelial lines were assayed for
invasion in the presence of LND from 1 to 50 mg/ml, the
number of invaded cells, compared with the positive control,
was reduced by about 20%, 40%, and 80%, respectively.
Similar results were obtained using BAEC and EA.hy926
cells (data not shown).
LND Inhibits Endothelial Cell Morphogenesis
In addition to its effect on endothelial cell proliferation and
apoptosis, we tested whether LND prevented the alignment
of endothelial cells in a capillary-like structure—an endothe-
lial function crucial to angiogenesis. As shown in Figure 3,
when HMVEC, HUVEC, EA.hy926, and BAEC lines were
plated on matrigel in the presence of NIH 3T3 CM (positive
control, panel a), they aligned with one another and formed
tube-like structures resembling a capillary plexus. In con-
trast, the addition of 5 mg/ml LND resulted in an inhibition of
this cord formation (panel b). Cells remained spherical, and
isolated and few aggregated cells were observed. This
picture resembled that obtained with the negative control
(data not shown). Even though HMVECs seem more affect-
ed by LND than other endothelial cell lines, all the parame-
ters previously analyzed after LND treatment, such as
proliferation, invasion, and migration, are indicative of a
superimposable effect of LND in the four endothelial cell
lines. Thus, we exclude a different sensitivity to LND treat-
ment between HMVECs and other endothelial cells.
LND Reduces Metalloproteases Secretion
Angiogenesis involves the acquisition by endothelial cells
of the capability to degrade the basement membrane and, in
general, to remodel the extracellular matrix [31]. Thus, we
examined whether treatment with LND at doses of 5 and 50
mg/ml for 48 hours could lead to a decrease in proteases
secretion by HUVEC and HMVEC (Figure 4). In the zymo-
graphic analysis of the CM from untreated cells, high levels
of secreted 72-kDa gelatinase (also designed MMP2) and
92-kDa gelatinase (also designed MMP9) were found in both
Figure 3. LND inhibits HMVEC, HUVEC, EA.hy926, and BAEC morpho-
genesis. Endothelial cells were plated on matrigel in the absence (panel a) or
in the presence (panel b) of LND at a dose of 5 g/ml and photographed.
Experiments were repeated at least three times, and each dose was tested in
triplicate. Representative phase-contrast micrographs are presented.
Figure 4. LND reduces metalloproteases secretion of HUVEC and HMVEC.
CM of endothelial cells incubated for 48 hours in SFM in the absence or
presence of LND at doses of 5 and 50 g/ml were collected and analyzed for
gelatin zymography (A) and Western blotting analysis (B). Proteins from an
equivalent number of viable cells were loaded. Red Ponceau staining of filter
was used to check equal loadings of proteins. (A) White bands against a dark
background correspond to the gelatinolytic areas of MMP2 (72 kDa) and
MMP9 (92 kDa) activity. (B) Western blot analysis of MMP2 and MMP9
proteins in HUVECs. Representatives of two independent experiments are
shown.
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endothelial lines (Figure 4A). A dose-dependent decrease in
the intensity of the bands was observed for both MMP2 and
MMP9 in the two endothelial lines. Similar results were
obtained when zymographic analysis was performed, both
loading CM from equal amounts of viable cells (Figure 4A)
and equal amounts of proteins (data not shown).
These results were confirmed by Western blot analysis of
HUVEC CM, demonstrating that LND treatment led to a
decrease in the expression of the pro-MMP2 (72 kDa) and
its active form (68 kDa) and the MMP9 proteins (Figure 4B).
Red Ponceau staining of filter was used to check equal
loading of proteins.
LND Reduces Vessel Formation in In Vivo Matrigel Assay
The effect of LND on in vivo angiogenesis was evaluated
by using the model of matrigel assay [26]. Matrigel plugs
containing heparin, VEGF, and two different doses of LND
(1 and 5 mg/ml) were injected subcutaneously in mice and
the degree of vascularization into matrigel plugs was evalu-
ated after 5 days. Macroscopic analysis of matrigel plugs
containing VEGF (positive control) showed intense vascu-
larization (Figure 5A), whereas the matrigel implant contain-
ing both VEGF and two different doses of LND were not able
to produce such blood vessel formation. Negative control
matrigel plugs, in which matrigel was injected with heparin
alone, showed only a slight local reaction or angiogenic re-
sponse (data not shown). The angiogenic response ob-
served by macroscopic analysis was consistent with the
quantitative results obtained by measuring the Hb levels
in the matrigel. As evident in Figure 5B, Hb content in the
matrigel plugs, containing both doses of LND, was signifi-
cantly lower than in those containing positive control (four
and eight times less for 1 and 5 mg/ml LND, respectively).
The highest dose of LND (5 mg/ml) showed an angiogenic
response similar to that observed for negative control. His-
tologic examination of vessels into matrigel plugs confirmed
the results of quantitative analysis of Hb (Figure 5C). Matri-
gel plugs from control mice (panel a) revealed a marked
capillary vessel proliferation, as compared with animals
treated with 5 mg/ml LND (panel b).
Effect of LND on Tumor Cell Proliferation, Migration,
Invasion, and Metalloproteases Production
The ability of LND to modulate tumor cell growth and to
trigger the apoptotic program on several tumor cell lines with
different histotype was also analyzed. Figure 6A shows the
effect of LND on proliferation of ADFS glioblastoma, JR8
melanoma, CG5 breast, and H460 lung carcinoma lines. It
is evident that the doses ranging from 1 to 10 mg/ml were
completely ineffective on all cell lines used, whereas treat-
ment with 25 mg/ml LND induced a reduction of cell prolifer-
ation only in JR8 melanoma (P < .05). A significant reduction
(P < .01) in cell numbers (about 60%) was observed when
the different lines were exposed to 50 mg/ml LND. Similar
results were obtained by exposing NIH 3T3 mouse fibro-
blasts to LND (data not shown). In addition, although doses
of LND ranging from 1 to 10 mg/ml did not induce apoptosis,
the 50-mg/ml dose activated the apoptotic program in all the
tumor lines by about 20% to 25% of cells (Figure 6B). These
data clearly demonstrate that the inhibitory activity of low-
doses LND on cell proliferation was only restricted to endo-
thelial cells, whereas the 50-mg/ml dose triggered apoptosis
both in endothelial and tumor cell lines.
Zymographic analysis of MMP2 and MMP9 was per-
formed in CM of two tumor cell lines with different histotypes:
CG5 human breast carcinoma and JR8 human melanoma,
untreated or treated with LND for 48 hours (Figure 7A). Low
levels of secreted MMP9 and high levels of secreted MMP2
were found in the two untreated tumor cell lines (Figure 7A).
No reduction of MMP2 and MMP9 production was observed
in either cell lines treated with 5 mg/ml LND, whereas a slight
decrease in MMP2 was observed after exposure to 50 mg/ml
LND. Western blot analysis of MMP2 protein expression
confirmed zymographic results (data not shown).
Migration and invasion of tumor cells in response to
different doses of LND (5 and 50 mg/ml) were also evaluated
in JR8 human melanoma. As shown in Figure 7, no signif-
icant differences in migration (Figure 7B) and invasion
(Figure 7C) were observed between untreated and LND-
treated tumor cells.
Discussion
The study described here demonstrated, for the first time,
that LND inhibits endothelial cell functions involved in angio-
genesis, and vessel formation in an in vivo matrigel assay.
We also found that LND does not affect in vitro cell prolifer-
ation, migration, invasion, and matrix metalloproteinases
production of different tumor lines. Using several endothelial
cell lines of different origin, we found that LND inhibits the
angiogenic process through effects on both induction and
resolution phases of the angiogenic cascade. In the induction
phase of angiogenesis, LND inhibited in vitro proliferation,
migration, and invasion, whereas in the resolution phase,
LND inhibited endothelial cell morphogenesis. The ability of
LND to decrease MMP2 and MMP9 secretion by endothelial
cells was also demonstrated, indicating that LND causes a
shift toward antiproteolysis in these cells. These results are
in agreement with observations that matrix metalloprotei-
nases play a key role in angiogenesis, and positive proteo-
lytic balance is required for capillary sprout elongation and
lumen formation during angiogenesis [31–35]. In particular,
it was found that MMP2 modulates the morphology of
endothelial structures, as well as their invasive behavior in
in vitro and in vivo assay systems [32], and that MMP9
contributes to angiogenesis and growth of human tumors
[35]. The in vitro activity of LND across all phases of the
angiogenic process was confirmed by an in vivo angiogenic
assay. LND significantly reduces vessel formation and inhib-
its the propensity of vessels to grow toward the matrigel plug.
All these effects were inhibited in a dose-dependent manner.
Inhibition of angiogenesis was already observed at low
doses of LND, and increased at higher doses. The antian-
giogenic activity of LND we observed in vitro and in vivo does
not exclude an eventual antivascular property of LND. Anti-
angiogenic activity and vascular damage have been dem-
onstrated for both old antineoplastic drugs (such as
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doxorubicin) and new drugs (such as selective cytokine-
inhibitory drugs) [36,37]. Further in vivo studies on tumor-
bearing animals might evidence whether in vivo LND
treatment affects already existing tumor vasculature, lead-
ing to damage to tumor blood vessel structure or function
such as vascular shutdown, tumor blood flow reduction,
and loss of immature tumor vessels.
The results obtained using annexin V assay after LND
treatment of endothelial cells show that LND does not induce
apoptosis at the lowest doses used (1–10 mg/ml) but
Figure 5. LND reduces vessel formation in a matrigel plug. Vessel formation was assessed after injection of C57BL/6 mice with matrigel plugs containing VEGF
alone (positive control) or in combination with two different doses of LND (1 and 5 g/ml). After 5 days, mice were sacrificed, and neovascularization and Hb content
of matrigel pellets were evaluated. (A) Macroscopic analysis of matrigels from one representative experiment. (B) Hb content of matrigel plugs. The negative
control contained heparin alone. The values were expressed as OD/100 mg of matrigel plug. The OD for each matrigel plug is reported (5). (C) Histologic analysis
of matrigel plugs from control mice (panel a) reveals a marked capillary vessel proliferation, as compared with animals treated with LND (panel b). (Masson
Trichrome stain; original magnification, 10).
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produces a cytotoxic effect at the highest dose employed
(50 mg/ml), thus indicating that the cytotoxic effect produced
by the high doses of LND on proliferating endothelial cells
could be due, at least in part, to an induction of apoptosis.
Likewise, several endogenous and exogenous angiogenesis
inhibitors have been demonstrated to induce endothelial cell
apoptosis, which in turn may be responsible for inhibiting
angiogenesis [38].
Experiments are in progress to explain how LND af-
fects the proliferation, invasion, migration, and matrix
Figure 7. LND does not inhibit metalloproteases secretion, migration, and invasion of tumor cells. CM of tumor cells incubated for 48 hours in SFM in the absence
or presence of LND at doses of 5 and 50 g/ml were collected and analyzed for MMP9 and MMP2 gelatin zymography (A) at an equivalent number of viable cells.
Representative experiments out of two are reported. Migration (B) and invasion (C) of untreated or LND-treated JR8 melanoma cells in response to NIH 3T3 CM.
The migrated or invaded cells were counted in at least four HPFs (200). Each value is the mean of quadruplicates ±SD, and the data are representative of at least
three separate experiments.
 
Figure 6. Low doses of LND do not inhibit tumor cell proliferation (A) and do not induce apoptosis (B). ADFS, CG5, JR8, H460, and cells were exposed for 48 hours
to doses of LND ranging from 1 to 50 g/ml. (A) Cell proliferation of JR8 (black column), CG5 (dark gray column), ADFS (pale gray column), and H460 (white
column) cells was evaluated after incubation of cells in 10% FCS in the absence (control) or in the presence of LND. Each value is the mean of sextuplicates ±SD,
and the data are representative of at least three separate experiments. Statistical differences between LND-treated versus untreated groups (positive control):
*P < .05; **P < .01. (B) Flow cytometric analysis of annexin V. The percentage of annexin V–positive cells is reported. A representative experiment out of three
is reported.
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metalloproteinase production in endothelial cells. Because
one of the major metabolic changes induced by LND is
inhibition of lactate transport and its accumulation, which
leads to intracellular acidification, we can hypothesize that
LND-induced acidification can be responsible for LND effect
on endothelial cell functions [8,12]. In fact, low pH has been
suggested to play a role in the relative specificity, efficacy,
and mechanism of action of the antiangiogenic factor,
angiostatin [39]. In addition, the mitochondrial membrane
permeabilization and dysfunction in energy metabolism in-
duced by LNDmay mediate its downregulation of endothelial
cell functions [9,10,15]. The inactivation of adenine nucleo-
tide translocase, a target of LND, has been found to inhibit
angiogenesis and proliferating—but not growth-quiescent—
endothelial cells [40]. Finally, because LND has been dem-
onstrated to increase cytosolic Ca2+ [41], and because
intracellular Ca2+ signaling may initiate or mediate some of
the cellular actions of endostatin and angiostatin, Ca2+
modulation by LND may represent another mechanism
through which LND exerts its effects on endothelial cell
functions [42]. It should be also considered that the effects
of LND in terms of cell growth inhibition or induction of
apoptosis may not be directly mediated by the drug, but
may be a secondary event induced by the drug such as
modulation of the expression of genes or proteins involved
in proliferation or apoptosis.
We have previously demonstrated that LND induces
apoptosis in breast cancer cells at the dose of 50 mg/ml
[19,20], and other authors found that LND triggers apoptosis
in leukemic cells at the dose of 65 mg/ml [14]. Thus, the effect
of different doses of LND was tested on tumor cell prolifer-
ation, migration, invasion, and apoptosis. We found that low
doses of LND (5 mg/ml) were not able to affect proliferation,
invasion, migration, and metalloproteases secretion, or to
induce apoptosis of human tumor cell lines (melanoma,
glioblastoma, breast, and lung). Thus, the inhibition of endo-
thelial cell functions essential for angiogenesis, by low doses
of LND, was not associated with cytotoxicity or induction of
endothelial or tumor cell death. This characteristic is an
important consideration for the possible therapeutic useful-
ness of the drug.
In conclusion, our results provide a novel mechanism of
action for LND and indicate that LND can be used to treat a
wide spectrum of angiogenesis-related neoplasms. The ob-
servation that the effect of low doses of LND is restricted to
endothelial cells suggests the use of LND at ‘‘metronomic’’
dosing [43] or ‘‘antiangiogenic chemotherapy’’ [44]. Due to
the low rate of endothelial cell division compared with tumor
cells, and because the damage to the tumor’s vasculature
can be largely repaired during the long breaks between
successive cycles of chemotherapy, standard chemother-
apeutic protocols are weakly effective on endothelial cells.
Shortening the time between cycles minimizes the efficacy of
the repair process, requiring the use of lower doses of drugs.
Thus, several studies suggest a potential complementary
strategy for rescheduling the administration of classic cyto-
toxic drugs to target tumor vasculature [44,45]. Most drugs,
belonging to virtually every class of anticancer chemother-
apeutic agents, showed more efficacy when the regimen
was switched to a lower-dose, more frequent schedule
[43–49], and the toxicity and rapid development of drug re-
sistance were not observed with this type of treatment [44].
On the contrary, high doses of LND that correspond to the
dose employed for clinical management of tumor target
multiple cell types of tumors and endothelial cells, not only
through inhibition of proliferation but also through induction of
apoptosis, thus indicating that the previously undescribed
antiangiogenic effect may be a significant contributor to the
antitumor effect of LND.
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